Actinoquinazolinone, a New Quinazolinone Derivative from a Marine Bacterium Streptomyces sp. CNQ-617, Suppresses the Motility of Gastric Cancer Cells.
Sultan PulatDa-Ae KimPrima F HillmanDong-Chan OhHangun KimSang-Jip NamWilliam FenicalPublished in: Marine drugs (2023)
A HPLC-UV guided fractionation of the culture broth of Streptomyces sp. CNQ-617 has led to the isolation of a new quinazolinone derivative, actinoquinazolinone ( 1 ), as well as two known compounds, 7-hydroxy-6-methoxy-3,4-dihydroquinazolin-4-one ( 2 ) and 7-methoxy-8-hydroxy cycloanthranilylproline ( 3 ). The interpretation of 1D, 2D NMR, and MS spectroscopic data revealed the planar structure of 1 . Furthermore, compound 1 suppressed invasion ability by inhibiting epithelial-mesenchymal transition markers (EMT) in AGS cells at a concentration of 5 µM. In addition, compound 1 decreased the expression of seventeen genes related to human cell motility and slightly suppressed the signal transducer and activator of the transcription 3 (STAT3) signal pathway in AGS cells. Together, these results demonstrate that 1 is a potent inhibitor of gastric cancer cells.
Keyphrases
- epithelial mesenchymal transition
- induced apoptosis
- signaling pathway
- cell cycle arrest
- ms ms
- single cell
- mass spectrometry
- poor prognosis
- multiple sclerosis
- magnetic resonance
- endothelial cells
- biofilm formation
- oxidative stress
- high resolution
- gene expression
- electronic health record
- molecular docking
- cell proliferation
- cell death
- staphylococcus aureus
- cell migration
- mesenchymal stem cells
- simultaneous determination
- immune response
- cystic fibrosis
- inflammatory response
- bone marrow
- anti inflammatory
- solid phase extraction
- data analysis
- drug induced
- candida albicans